Solid Biosciences Inc.
SLDB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001707502
No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Solid Biosciences Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 37 | 40 | +3 |
| Shares | 16.2M | 16.6M | +463.8K (+2.9%) |
| Value | $40.7M | $102.2M | +$61.5M (+150.9%) |
New holders (8)
Institutions that held Solid Biosciences Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Silverarc Capital Management, LLC | 594,855 | $3.65M | 1.13% |
| Bank of Montreal | 131,500 | $900.8K | 0.00% |
| Two Sigma Investments, LP | 37,198 | $228.4K | 0.00% |
| Vestal Point Capital, LP | 34,085 | $209.3K | 0.02% |
| Susquehanna International Group, LLP | 33,235 | $204.1K | 0.00% |
| AJOVista, LLC | 3,806 | $23.4K | 0.03% |
| ADAR1 Capital Management, LLC | 1,000 | $6.14K | 0.00% |
| Hantz Financial Services, Inc. | 666 | $4.00K | 0.00% |
Sold out (5)
Institutions that held Solid Biosciences Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Great Point Partners LLC | 450,403 | $1.14M |
| Caas Capital Management LP | 64,112 | $161.6K |
| Lazard Asset Management LLC | 2,332 | $5.00K |
| Manchester Capital Management LLC | 1,000 | $2.52K |
| Group One Trading, L.P. | 214 | $539 |